1. Home
  2. SAM vs JANX Comparison

SAM vs JANX Comparison

Compare SAM & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

HOLD

Current Price

$199.75

Market Cap

2.1B

ML Signal

HOLD

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$13.31

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAM
JANX
Founded
1984
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.8B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
SAM
JANX
Price
$199.75
$13.31
Analyst Decision
Hold
Strong Buy
Analyst Count
10
12
Target Price
$245.11
$60.27
AVG Volume (30 Days)
154.2K
2.3M
Earning Date
02-24-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
23.12
N/A
EPS
8.25
N/A
Revenue
$1,981,609,000.00
$10,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.75
N/A
P/E Ratio
$23.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$185.34
$13.28
52 Week High
$298.99
$61.59

Technical Indicators

Market Signals
Indicator
SAM
JANX
Relative Strength Index (RSI) 52.05 26.48
Support Level $193.61 $13.28
Resistance Level $198.61 $14.49
Average True Range (ATR) 3.89 0.47
MACD 0.42 0.36
Stochastic Oscillator 58.73 3.68

Price Performance

Historical Comparison
SAM
JANX

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: